Journal of substance use and addiction treatment最新文献

{"title":"TOC (update)","authors":"","doi":"10.1016/S2949-8759(25)00113-4","DOIUrl":"10.1016/S2949-8759(25)00113-4","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"175 ","pages":"Article 209734"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144253367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between buprenorphine adherence for opioid use disorder and clinical events and healthcare spending among older patients","authors":"Olajumoke A. Olateju ,&nbsp;Mina Shrestha ,&nbsp;J. Douglas Thornton","doi":"10.1016/j.josat.2025.209740","DOIUrl":"10.1016/j.josat.2025.209740","url":null,"abstract":"<div><h3>Background</h3><div>Buprenorphine adherence in older adults with opioid use disorder (OUD) remains underexplored. This study investigated the associations between buprenorphine adherence and risks of opioid overdose, hospitalization, and healthcare spending among older adults to help inform practice and policy.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, we utilized the Merative MarketScan® Database (2017–2019) to identify Medicare Advantage enrollees with OUD who initiated buprenorphine and were retrospectively followed for 180 days. We classified patients as adherent (Proportion of Days Covered ≥0.80) or non-adherent to buprenorphine. We balanced baseline characteristics between groups using an inverse probability treatment weighting approach. We then evaluated the associations between adherence and the risks of opioid overdose and all-cause hospitalization using discrete-time survival and Cox proportional hazards models respectively. Finally, we estimated differences in healthcare spending between adherent and non-adherent patients using generalized linear models.</div></div><div><h3>Results</h3><div>The cohort included 631 patients (379 [60 %] male; mean (SD) age:67 [2.8] years). Among them, 437 (69 %) were adherent to buprenorphine. Patients with a history of chronic pain, mental health disorders, and diabetes were less likely to adhere while higher average daily doses of buprenorphine were associated with increased adherence. Adherence was associated with reduced risks of opioid overdose (HR:0.76; 95%CI:0.59–0.93) and hospitalization (HR:0.55; 95%CI:0.42–0.73). Healthcare spending among adherent patients was $40,200 [95%CI:$54,712-25,687]) lower than in non-adherent patients. These findings were consistent across robustness and sensitivity analyses.</div></div><div><h3>Conclusions</h3><div>Buprenorphine adherence was associated with reduced risks of opioid overdose, hospitalization, and healthcare spending in the overall population of older individuals with OUD. Enhancing adherence to buprenorphine should be prioritized in OUD treatment strategies among this population.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209740"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C2: editorial board","authors":"","doi":"10.1016/S2949-8759(25)00112-2","DOIUrl":"10.1016/S2949-8759(25)00112-2","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"175 ","pages":"Article 209733"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144253366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of state medicaid prescription cap policies with trajectories of buprenorphine use for opioid use disorder","authors":"Patience M. Dow ,&nbsp;Miriam George ,&nbsp;Landon D. Hughes ,&nbsp;Corinne Roma ,&nbsp;Theresa I. Shireman ,&nbsp;Julie M. Donohue ,&nbsp;Lisa Peterson ,&nbsp;Jaclyn M.W. Hughto","doi":"10.1016/j.josat.2025.209739","DOIUrl":"10.1016/j.josat.2025.209739","url":null,"abstract":"<div><h3>Background</h3><div>Buprenorphine and other medications for opioid use disorder (OUD) can reduce opioid-related morbidity and mortality. It is unknown whether state Medicaid prescription cap policies that restrict the monthly number of covered prescription fills affect the duration of buprenorphine use.</div></div><div><h3>Objective</h3><div>To identify trajectories of buprenorphine use and determine the association of caps with trajectory group membership among individuals with OUD.</div></div><div><h3>Methods</h3><div>Using 10 states' Medicaid claims data from 2010 to 2015, we employed group-based trajectory models to identify patterns of buprenorphine fills over 12 months. We conducted multinomial logistic regression to estimate the association of cap policies with buprenorphine trajectory group membership, adjusting for individual- and state-level covariates.</div></div><div><h3>Results</h3><div>Among 69,306 Medicaid enrollees with OUD who initiated buprenorphine, 16.9 % resided in states with caps. The mean age was 36.2 (SD = 9.8) years and 59.2 % were female. We identified five trajectories: consistent use (40.9 %), delayed discontinuation (14.5 %), early discontinuation (26.4 %), gradually declining use (9.5 %), and rebounding use (8.8 %). Caps were associated with greater risk of membership in the early discontinuation group (adjusted relative risk ratio = 1.47, 95%CI = 1.36,1.59, referent = consistent use). Younger age, male sex, Black race, Hispanic ethnicity, non-opioid substance use disorder, history of acute care utilization were also positively associated with early discontinuation.</div></div><div><h3>Conclusions</h3><div>Medicaid cap policies were associated with increased likelihood of early discontinuation and other trajectories of inconsistent buprenorphine use relative to states without these policies. Medicaid's prominence as a payer for OUD treatment and 12 states' continued implementation of caps warrant safeguards to ensure cap policies do not undermine buprenorphine access.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209739"},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOC (update)","authors":"","doi":"10.1016/S2949-8759(25)00107-9","DOIUrl":"10.1016/S2949-8759(25)00107-9","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"174 ","pages":"Article 209728"},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144241753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C2: editorial board","authors":"","doi":"10.1016/S2949-8759(25)00106-7","DOIUrl":"10.1016/S2949-8759(25)00106-7","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"174 ","pages":"Article 209727"},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144241752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicaid health home design and buprenorphine receipt, 2009–2020","authors":"Christina M. Andrews ,&nbsp;Theodoros Giannouchos ,&nbsp;Angela Rogers ,&nbsp;Melissa A. Westlake","doi":"10.1016/j.josat.2025.209738","DOIUrl":"10.1016/j.josat.2025.209738","url":null,"abstract":"<div><h3>Introduction</h3><div>In the midst of an escalating opioid epidemic, innovative models of care are critical to expand access to opioid use disorder treatment. The Medicaid health home program, which costs the nation $1 billion annually, is intended to improve identification and treatment for enrollees with complex chronic conditions, including opioid use disorder. In this study, we assess the association of state-level Medicaid health home policies related to substance use disorder screening and health home eligibility with trends in prescriptions for buprenorphine, a medication that dramatically reduces risk of opioid-related overdose and mortality.</div></div><div><h3>Methods</h3><div>We use Medicaid data on buprenorphine prescriptions from 2009 to 2020 and a difference in differences methodology accounting for variation in treatment timing. Our treatment groups are states that require health homes to screen for substance use disorder and states that had at least one health home that has substance use disorder as a qualifying condition.</div></div><div><h3>Results</h3><div>We find no significant difference in rates of buprenorphine prescriptions filled among states that require screening for substance use disorder and those that do not. We also do not find significant differences in buprenorphine prescriptions between states that designate substance use disorder as a qualifying condition for health home participation and those that do not.</div></div><div><h3>Conclusion</h3><div>Health home policies intended to reach opioid use disorder patients are not increasing buprenorphine receipt, which is one key measure of opioid use disorder treatment. State Medicaid programs should assess strategies to enhance health home performance in facilitating access opioid use disorder treatment.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209738"},"PeriodicalIF":0.0,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144253427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of substance use disorder and mental health disorder treatment facilities with perinatal programs","authors":"Brooke N. Lombardi ,&nbsp;Anna B. Parisi ,&nbsp;Helen Newton ,&nbsp;Brianna M. Lombardi","doi":"10.1016/j.josat.2025.209722","DOIUrl":"10.1016/j.josat.2025.209722","url":null,"abstract":"<div><h3>Background</h3><div>Substance use disorders (SUD) and mental health disorders (MHD) are major health concerns during the perinatal period (conception to one year postpartum). However, many individuals with perinatal SUD or MHD do not receive adequate treatment, and most treatment facilities do not offer services tailored to this population's unique needs. This study examines the proportion of treatment facilities in the United States (US) providing perinatal services, as well as facility- and state-level factors associated with offering such services.</div></div><div><h3>Methods</h3><div>Data were drawn from the 2022 National Substance Use and Mental Health Services Survey, an annual cross-sectional survey of all known public and private SUD and MHD treatment facilities in the US. The sample consisted of 6995 facilities providing SUD treatment (SUD-only) and 9134 facilities offering combined SUD and MHD treatment. Descriptive statistics, bivariate analyses, and multilevel logistic regression models examined treatment facility characteristics and the impact of facility- and state-level factors on the likelihood of offering perinatal services.</div></div><div><h3>Results</h3><div>Only 32.7% of SUD-only treatment facilities and 31.1% of combined SUD/MHD treatment facilities offered perinatal programs. More than half of these treatment facilities provided services critical to the perinatal population, including transportation assistance, social service support, trauma-informed therapy, and telehealth. Payment type (i.e., Medicaid acceptance, offer of free or low-cost treatment), for-profit treatment facility ownership, and receipt of state and federal grant funding were associated with a significantly increased likelihood of the treatment facility providing perinatal services.</div></div><div><h3>Conclusions</h3><div>Findings indicate there is a pressing need for SUD and MHD treatment facilities to expand their services to include care for individuals in the perinatal period, as well as increase the availability of essential services (e.g., integrated primary care) and ancillary services (e.g., childcare). Further research is needed to understand at which timepoint(s) facilities provide treatment (i.e., pregnancy and/or the postpartum period) and which types of essential and ancillary services are most beneficial during the perinatal period.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209722"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"I will always be a mother. Now, I am an advocate","authors":"Amy Bogert,&nbsp;Jack J. Lu","doi":"10.1016/j.josat.2025.209724","DOIUrl":"10.1016/j.josat.2025.209724","url":null,"abstract":"<div><h3>Background</h3><div>Mason Bogert lived a brilliant life. His struggle with co-occurring substance use and mental health conditions culminated into lifelong paths of recovery for him and his mother, Amy Bogert.</div></div><div><h3>Methods</h3><div>Amy shares her lived experience as Mason's parent and caregiver alongside a national context of youth co-occurring disorder prevalence and resulting effects. Best practice and evidence-based strategies are identified, such as family involvement, integrated treatment, and youth-empowered community level prevention.</div></div><div><h3>Results</h3><div>Presently, Amy focuses on advocacy for youth co-occurring and substance use care across a continuum of prevention, integrated treatment, and recovery services. Amy's deepest hope is that youth, like Mason, and their loved ones experience less isolation and more opportunities in preventing the progression of co-occurring and substance use disorders.</div></div><div><h3>Conclusions</h3><div>Evidence-based youth co-occurring prevention and integrated treatment services are essential for youth and their families.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"175 ","pages":"Article 209724"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144167424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing unmet need for substance use disorder treatment among youth in the legal system (YLS): Costs of structured implementation interventions with juvenile justice agencies in seven states","authors":"Kathryn E. McCollister ,&nbsp;Diana Bowser ,&nbsp;Jenny E. Becan ,&nbsp;Danica K. Knight ,&nbsp;Steven Belenko ,&nbsp;Angela A. Robertson ,&nbsp;Michael L. Dennis","doi":"10.1016/j.josat.2025.209721","DOIUrl":"10.1016/j.josat.2025.209721","url":null,"abstract":"<div><h3>Introduction</h3><div>Implementation of integrated strategies for improving access to behavioral health services for youth in the legal system requires evidence of the costs of changing existing practices, and stakeholders need to be aware of what types of investments (e.g., personnel, data systems) lead to more efficient implementation and better outcomes.</div></div><div><h3>Methods</h3><div>A cost analysis was conducted alongside the Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System (JJ-TRIALS), a research cooperative comprising 34 community supervision agencies in seven states that were randomly assigned to Core or Core+Enhanced implementation interventions. Both were focused on improving screening, referral, and linkage to behavioral health services for youth with substance use disorders (SUD). Cost data were collected prospectively across all implementation phases.</div></div><div><h3>Results</h3><div>During Baseline, the average cost was $11,083 per site (range: $1104 to $19,399). Enhanced sites had relatively higher baseline costs ($13,176 vs. $9222 in the Core sites). During the Experiment phase, Enhanced sites continued to incur higher implementation costs relative to the Core sites, but these costs steadily declined and ultimately converged with Core sites as they entered the sustainment phase.</div></div><div><h3>Conclusions</h3><div>Enhanced sites had higher implementation costs; but both Enhanced and Core sites showed similar trends in decreasing costs across the Experiment period. These decreasing costs reflected both fewer meetings and lower participation over time. In a funding climate where available resources are already scarce, access to cost data can help agencies prepare to implement and sustain new practices.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209721"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}